Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

Related Videos
Che-Kai Tsao, MD
Xingming Zhang, MD
Samer A. Srour, MB ChB, MS
Expert on RCC
Experts on RCC
Brian I. Rini, MD, FASCO
Eric A. Singer, MD
Che-Kai Tsao, MD
Matthew Galsky, MD
Christopher W. Ryan, MD
Related Content